FAM47B: A Drug Target / Disease Biomarker (G170062)

Target Name: FAM47B

NCBI ID: G170062

FAM47B

Other Name(s): family with sequence similarity 47 member B | Protein FAM47B | FLJ35782 | Family with sequence similarity 47 member B | FA47B_HUMAN

FAM47B: A Drug Target / Disease Biomarker

Fam47B, also known as FAM47B-P2, is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a member of the FAM47 family of proteins, which are known for their role in cell signaling. The FAM47B gene has been identified and is located on chromosome 16p13.3.

One of the unique features of Fam47B is its ability to interact with various signaling pathways. This protein has been shown to play a role in several signaling pathways, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the Wnt signaling pathway.

Fam47B has also been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that Fam47B is overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. This suggests that Fam47B may be a potential drug target or biomarker for these diseases.

In addition to its potential clinical applications, Fam47B is also of interest to researchers because of its unique structure and function. The FAM47B protein is composed of 191 amino acid residues and has a calculated molecular weight of 21.1 kDa. It has a distinct N-terminal region that is involved in its localization and function, as well as a C-terminal region that is involved in its stability and interactions with other proteins.

The N-terminal region of Fam47B contains a putative N-endopeptide insertion (NED) domain, which is known for its ability to interact with other proteins. This domain is composed of three amino acids: Asp-221, Asp-222, and Asp-223. The NED domain is involved in the formation of a binary structure with other proteins, which may be important for its function.

The C-terminal region of Fam47B contains a calcineurin-like domain (CUD) and a leucinerich repeat (LRR) domain. The CUD is involved in the regulation of protein stability, and the LRR domain is involved in the formation of protein-protein interactions.

Fam47B has been shown to play a role in several signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and is a potential target for several drugs, including anti-cancer agents.

Fam47B has also been shown to play a role in the regulation of the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival. This pathway is a potential target for drugs that are used to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Fam47B has also been shown to play a role in the regulation of the Wnt signaling pathway, which is involved in the regulation of cell growth, survival, and angiogenesis. This pathway is a potential target for drugs that are used to treat developmental disorders, such as Down syndrome and neural tube defects.

In conclusion, Fam47B is a protein that is expressed in various tissues of the body and is involved in several signaling pathways. Its unique structure and function make it an interesting potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of Fam47B in these diseases and to develop safe and effective treatments.

Protein Name: Family With Sequence Similarity 47 Member B

The "FAM47B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM47B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets